6/6/2023 0 Comments Initial d street stage aura![]() ![]() AU-011, our first VDC candidate, is being developed for the first line treatment of primary choroidal melanoma, a rare disease with no drugs approved. Our VDCs are largely agnostic to tumor type and can recognize a surface marker that is specifically modified and broadly expressed on many tumors. ![]() Our proprietary platform enables the targeting of a broad range of solid tumors using Virus-Like Particles that can be conjugated with drugs or loaded with nucleic acids to create Virus-Like Drug Conjugates, or VDCs. Aura Biosciences is a clinical-stage biotechnology company leveraging our novel targeted oncology platform to develop a potential new standard of care across multiple cancer indications, with an initial focus on ocular and urologic oncology.
0 Comments
Leave a Reply. |